Ensuring the conformity of polymeric products for pharmaceutical use presents a dual challenge. These materials exhibit complex, statistical structures that require tight control over multiple parameters to ensure safety and efficacy. At the same time, the range of analytical technologies suitable for routine polymer analysis remains limited.
Image Credit: S. Singha/Shutterstock.com
Among the few techniques capable of meeting these demands, Nuclear Magnetic Resonance (NMR) stands out, offering direct, absolute measurements of key structural features. This whitepaper illustrates NMR’s capabilities in polymer analysis through the compendial testing of Linear Alcohol Ethoxylates (AEs), a significant class of non-ionic surfactants.
It highlights the Bruker Fourier 80 benchtop NMR spectrometer - a compact, cryogen-free system tailored for Quality Control (QC) laboratories. With built-in regulatory compliance features, the Fourier 80 delivers simple, cost-effective access to NMR technology. It supports both qualitative and quantitative testing of organic compounds and offers a versatile toolkit for routine and investigational polymer analysis.
Download the full whitepaper here.
About Bruker BioSpin Division
The Bruker BioSpin Division designs, manufactures, and distributes advanced scientific instruments based on magnetic resonance, preclinical imaging technologies, and biosensor technologies. These include our industry-leading NMR and EPR spectrometers, imaging systems utilizing MRI, PET, SPECT, CT, Optical and MPI modalities, as well as molecular interaction technologies like SPR, switchSENSE® and single-cell Interaction Cytometry (scIC). The Division also offers integrated software solutions and automation tools to support digital transformation across research and quality control environments.
Our customers in academic, government, industrial, and pharmaceutical sectors rely on these technologies to gain detailed insights into molecular structure, dynamics, and interactions. Our solutions play a key role in structural biology, drug discovery, disease research, metabolomics, and advanced materials analysis. Recent investments in lab automation, optical imaging, and contract research services further strengthen our ability to support evolving customer needs and enable scientific innovation.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.